Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease: Evidence, ARIA Risk, and Precision Patient Selection
Journal of Personalized Medicine · 15.09.2025 · 15 (9) · 437
DOI: 10.3390/jpm15090437 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 15.09.2025. Verfasst von Amer E Alkhalifa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery and Development, Harrison School of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, AL 36849, USA. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the most common cause of dementia, pathologically defined by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles. Recent U.S. Food and Drug Administration (FDA) approvals of anti-amyloid monoclonal antibodies (mAbs) aducanumab, lecanemab, and donanemab represent the first disease-modifying therapies for early AD. These therapies have generated both optimism and controversy due to modest efficacy and safety concerns, particularly amyloid-related imaging abnormalities (ARIAs). This review synthesizes current evidence on the efficacy, safety, and biomarker-guided use of anti-Aβ mAbs in AD.
Methods
We searched PubMed, Scopus, Web of Science, and Google Scholar to 31 July 2025 for studies on anti-amyloid mAbs in AD. Sources included peer-reviewed articles and regulatory reports. The extracted data covered study design, population, amyloid confirmation, dosing, outcomes, biomarkers, ARIA incidence, and management.
Results
Anti-amyloid mAbs consistently demonstrated robust amyloid clearance and modest slowing of clinical decline in early symptomatic AD. Differences emerged across agents in efficacy signals, safety profiles, and regulatory outcomes. Lecanemab and donanemab showed more consistent cognitive benefits, while aducanumab yielded mixed findings, leading to its withdrawal. ARIAs were the most frequent adverse events, occurring more often in APOE ε4 carriers and typically during early treatment. Biomarker analyses also revealed favorable downstream effects, including reductions in phosphorylated tau and markers of astroglial injury, supporting engagement of disease biology.
Conclusions
Anti-amyloid mAbs provide proof of concept for AD modification, with the greatest benefit in early disease stages and moderate tau burden. Optimal use requires biomarker confirmation of the amyloid, careful tau staging, and genetic risk assessment. While limitations remain, these therapies represent a pivotal step toward precision neurology and may serve as a foundation for multimodal strategies targeting tau, neuroinflammation, and vascular pathology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, AL 36849, USA.
- Faculty of Medicine, University of Science and Technology, Sana'a 15034, Yemen.
- Faculty of Pharmacy, Zonguldak Bülent Ecevit University, Zonguldak 67100, Türkiye.
ORCID-Profile: Amer E Alkhalifa, Nour F Al-Ghraiybah
Zitieren
APA
Alkhalifa, A. E., Al Mokhlf, A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025). Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease: Evidence, ARIA Risk, and Precision Patient Selection. Journal of Personalized Medicine, 15(9), 437. https://doi.org/10.3390/jpm15090437
Vancouver
Alkhalifa AE, Al Mokhlf A, Ali H, Al-Ghraiybah NF, Syropoulou V. Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease: Evidence, ARIA Risk, and Precision Patient Selection. Journal of Personalized Medicine. 2025;15(9):437. doi:10.3390/jpm15090437
BibTeX
@article{Alkhalifa2025,
author = {Alkhalifa, Amer E and Al Mokhlf, Abdulrahman and Ali, Hande and Al-Ghraiybah, Nour F and Syropoulou, Vasiliki},
title = {Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease: Evidence, ARIA Risk, and Precision Patient Selection},
journal = {Journal of Personalized Medicine},
year = {2025},
volume = {15},
number = {9},
pages = {437},
doi = {10.3390/jpm15090437}
}
EUVIMED